Loading…
Akari Therapeutics, Plc is projected to rise to $16.05 by 2027, a +16% move from its current price of $13.88. AKTX is currently trading above its 50-day average (a bullish sign). Technical indicators currently lean strong buy.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 7/11/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Jul 12 | $12.63 | $13.88 | $15.25 | +0.01% |
| Jul 13 | $12.15 | $13.88 | $15.86 | +0.01% |
| Jul 14 | $11.79 | $13.88 | $16.34 | +0.02% |
| Jul 15 | $11.50 | $13.88 | $16.76 | +0.03% |
| Jul 16 | $11.25 | $13.88 | $17.14 | +0.03% |
| Jul 17 | $11.03 | $13.89 | $17.49 | +0.04% |
| Jul 18 | $10.82 | $13.89 | $17.81 | +0.05% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $10.82 | $13.89 | $17.81 | +0.05% |
| Week 2 | $9.77 | $13.89 | $19.76 | +0.09% |
| Week 3 | $9.03 | $13.90 | $21.40 | +0.14% |
| Week 4 | $8.45 | $13.91 | $22.89 | +0.19% |
| Week 5 | $7.97 | $13.91 | $24.28 | +0.24% |
| Week 6 | $7.56 | $13.92 | $25.62 | +0.28% |
| Week 7 | $7.20 | $13.93 | $26.92 | +0.33% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Akari Therapeutics, Plc is an oncology company that develops antibody-drug conjugates (ADC) for cancer-killing toxins. Its lead payload is PH1 to disrupt the function of spliceosomes and to trigger an immune response that leads to additional cancer cell killing. The company’s lead product candidate is AKTX-101, a preclinical stage trop2-targeting ADC that combines PH1 with the trop2 antibody to treat solid tumor cancer types, including lung, breast, bladder, head and neck, gastric, pancreatic, colon, prostate, and others.
Its payloads include PH1 is a novel payload that is a spliceosome modulator designed to disrupt RNA splicing within cancer cells. The company also develops AKTX-102, a novel bispecific ADC that utilizes PH1 as its payload to treat various solid tumor cancers. Akari Therapeutics, Plc is headquartered in Tampa, Florida.
Akari Therapeutics, Plc (AKTX) is trading at $13.16 per share. Its market capitalization is $23.04M and it is ranked 4871. The price outlook shows a path from 2026 through 2050 with higher potential in later years; the average forecast price rises from 2026 through 2050, reaching $31.15 on average in 2050, with some years showing stronger gains and others showing modest declines.
The forecast indicates neutral sentiment in the near term, turning bullish in multiple later years as the price outlook expands to higher levels.
A major floor 81.1% below — a decisive break under it would weaken the trend.
The nearest floor, 31.4% below — buyers have tended to step in here.
The nearest ceiling, 58.9% above — a clean break opens room to run.
A major ceiling 99.4% above — clearing it would confirm fresh momentum.
Key AKTX support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of AKTX market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $13.53 | Buy | $13.27 | Buy |
| MA 10 | $11.90 | Buy | $12.61 | Buy |
| MA 20 | $11.98 | Buy | $12.23 | Buy |
| MA 50 | $10.60 | Buy | $11.07 | Buy |
| MA 100 | $8.82 | Buy | $11.17 | Buy |
| MA 200 | $14.60 | Sell | $17.11 | Sell |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 56.51 | Neutral |
| Stoch RSI (14) | 68.22 | Neutral |
| CCI (20) | 82.78 | Neutral |
| Williams %R (14) | -26.85 | Info |
| MACD (12,26,9) | 0.22 | Buy |
| ROC (12) | 17.73 | Buy |
| Bollinger %B (20,2) | 0.77 | Neutral |
| Stochastic %K (14) | 73.15 | Neutral |
| TRIX (15) | 0.25 | Buy |
| Awesome (5,34) | 0.17 | Buy |
| Ultimate (7,14,28) | 64.80 | Neutral |
| Momentum (10) | 4.36 | Buy |
| Aroon Osc (25) | -56.00 | Sell |
| Hull MA (9) | 14.95 | Sell |
| ADX (14) | 13.49 | Neutral |
| ATR (14) | 1.13 | Info |
Technical sentiment is BULLISH. The RSI(14) is 50. The 50-day simple moving average is $10.43 and the 200-day simple moving average is $14.70. Key levels include support at $9.52 and resistance at $22.05, with a 30-day range from $6.98 to $24.83.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $3.06 | $13.88 | $21.02 | 0% | Neutral | |
| $11.64 | $16.05 | $23.92 | +16% | Neutral | |
| $10.43 | $15.27 | $24.26 | +10% | Neutral | |
| $8.92 | $13.76 | $22.94 | -1% | Neutral | |
| $7.39 | $11.95 | $20.75 | -14% | Neutral | |
| $8.36 | $14.14 | $25.40 | +2% | Neutral | |
| $8.92 | $15.73 | $29.14 | +13% | Neutral | |
| $9.70 | $17.81 | $33.91 | +28% | Bullish | |
| $11.13 | $21.26 | $41.50 | +53% | Bullish | |
| $9.15 | $18.17 | $36.30 | +31% | Bullish | |
| $12.41 | $27.58 | $60.54 | +99% | Bullish | |
| $14.80 | $32.89 | $75.65 | +137% | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| July 2026 | $3.06 | $13.88 | $17.73 | +0.00% |
| August 2026 | $11.74 | $14.23 | $17.96 | +2.49% |
| September 2026 | $11.36 | $13.97 | $18.00 | -1.82% |
| October 2026 | $12.12 | $15.08 | $19.78 | +8.00% |
| November 2026 | $12.66 | $15.91 | $21.16 | +5.49% |
| December 2026 | $12.29 | $15.60 | $21.02 | -1.97% |
Click any year to see its month-by-month AKTX forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
Akari Therapeutics, Plc's 2026 outlook centres on $13.88, within a $3.06 to $21.02 range. That marks a 0% change versus current levels. A consolidation phase looks the most probable path here.
By 2027, AKTX could reach as high as $23.92, with a base case around $16.05 and support toward $11.64 — roughly +16% from $13.88. Price action looks broadly range-bound.
Expect AKTX to range from $10.43 to $24.26 through 2028. The $15.27 average target implies a +10% move from current prices. That is -5% versus the projected 2027 average. A consolidation phase looks the most probable path here.
The AKTX price prediction for 2029 points to an average of $13.76 (low $8.92, high $22.94) — a potential decline of -1% on today's $13.88. Price action looks broadly range-bound.
In 2030, AKTX is projected to trade between $7.39 and $20.75, averaging $11.95 — a potential decline of -14% from today's $13.88. That is -13% versus the projected 2029 average. A consolidation phase looks the most probable path here.
Akari Therapeutics, Plc's 2031 outlook centres on $14.14, within a $8.36 to $25.40 range. That is up +18% on the projected 2030 average. That marks a +2% change versus current levels. Price action looks broadly range-bound.
By 2032, AKTX could reach as high as $29.14, with a base case around $15.73 and support toward $8.92 — roughly +13% from $13.88. A consolidation phase looks the most probable path here.
Expect AKTX to range from $9.70 to $33.91 through 2033. The $17.81 average target implies a +28% move from current prices. That is up +13% on the projected 2032 average. Momentum favours further upside here.
The AKTX price prediction for 2034 points to an average of $21.26 (low $11.13, high $41.50) — a potential gain of +53% on today's $13.88. Buyers look set to stay in control over this stretch.
In 2035, AKTX is projected to trade between $9.15 and $36.30, averaging $18.17 — a potential gain of +31% from today's $13.88. That is -15% versus the projected 2034 average. Momentum favours further upside here.
Akari Therapeutics, Plc's 2040 outlook centres on $27.58, within a $12.41 to $60.54 range. That is up +52% on the projected 2035 average. That marks a +99% change versus current levels. Buyers look set to stay in control over this stretch.
By 2050, AKTX could reach as high as $75.65, with a base case around $32.89 and support toward $14.80 — roughly +137% from $13.88. Momentum favours further upside here.
Investing $1,000 in AKTX today (≈ 72.04611 AKTX) could be worth
$2,369.65
+$1,369.65 (+137%) by 2050 · US Dollar
Based on the average projected AKTX price of $32.89 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in AKTXwould be worth at today's price.
$1,000 invested in AKTX on Jul 10, 2025 (≈ 21.834061 AKTX) would be worth
$303.06
-$696.94 (-69.7%) today · 0.30× · US Dollar
Based on a AKTX entry price of $45.8 vs. today's $13.88.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $10.41 | $1,333.33 | +33.3% |
| 1 month ago | $14.63 | $948.74 | -5.1% |
| 3 months ago | $3.83 | $3,624.02 | +262.4% |
| 6 months ago | $11 | $1,261.82 | +26.2% |
| 1 year ago | $45.8 | $303.06 | -69.7% |
| All time (5.0y) ago | $1,328 | $10.45 | -99.0% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our AKTX forecast.
Our base-case forecast reaches $28.00 around 2050.
Implied market cap at $28.00: $49.01M
The year-by-year forecast shows a mixed near-term path and stronger longer-term upside. In 2026 the avg price is $13.16 with ROI 0 and Neutral sentiment, while 2027-2029 show modest upside and continued Neutral sentiment. The model projects a negative ROI in 2030 of -13.6 with an avg price of $11.37, before resuming gains in 2032-2035.
From 2033 onward the outlook turns bullish, with 2033 avg $16.93 and max $32.23 (ROI 28.6) and 2034 avg $20.16 (ROI 53.1) and 2035 avg $17.20 (ROI 30.7). The longer horizon shows substantial upside: 2040 avg $26.13 (ROI 98.5) and 2050 avg $31.15 (ROI 136.7), both with bullish sentiment.
Tap a question to reveal the answer.
The 2030 forecast shows an avg price of $11.37 with a range from $7.03 to $19.74 and a ROI of -13.6, with Neutral sentiment.
Near term is Neutral through 2032, with bullish potential emerging in later years and a long-run avg price of $31.15 in 2050 and ROI of 136.7, noting that these are estimates, not guarantees.
Yes. The forecast max in 2027 is $22.73, and higher in subsequent years (e.g., 2033 max $32.23 and 2034 max $39.35), indicating potential to surpass $22 within the forecast horizon.
Current price is $13.16 and market cap is $23.04M, with a rank of 4871.
2040 avg is $26.13 with ROI 98.5 and bullish sentiment; 2050 avg is $31.15 with ROI 136.7 and bullish sentiment.
Akari Therapeutics, Plc Community Discussion
0Share your Akari Therapeutics, Plc price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.